KR20170045343A - 피부의 장벽 기능의 ｕｖ-유도 상실을 치료하는데 사용하기 위한 국소 프테로스틸벤 조성물 - Google Patents

피부의 장벽 기능의 ｕｖ-유도 상실을 치료하는데 사용하기 위한 국소 프테로스틸벤 조성물 Download PDF

Info

Publication number
KR20170045343A
KR20170045343A KR1020177009080A KR20177009080A KR20170045343A KR 20170045343 A KR20170045343 A KR 20170045343A KR 1020177009080 A KR1020177009080 A KR 1020177009080A KR 20177009080 A KR20177009080 A KR 20177009080A KR 20170045343 A KR20170045343 A KR 20170045343A
Authority
KR
South Korea
Prior art keywords
skin
loss
topical
barrier function
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177009080A
Other languages
English (en)
Korean (ko)
Inventor
플랭크 엘. 주니어 메이스켄스
라이언 더블유. 델린저
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20170045343A publication Critical patent/KR20170045343A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y10S514/863—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
KR1020177009080A 2014-09-04 2015-09-03 피부의 장벽 기능의 ｕｖ-유도 상실을 치료하는데 사용하기 위한 국소 프테로스틸벤 조성물 Ceased KR20170045343A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046068P 2014-09-04 2014-09-04
US62/046,068 2014-09-04
PCT/US2015/048422 WO2016036999A1 (en) 2014-09-04 2015-09-03 Topical pterostilbene compositions for use in treating uv-induced loss of barrier function in skin

Publications (1)

Publication Number Publication Date
KR20170045343A true KR20170045343A (ko) 2017-04-26

Family

ID=55436471

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177009080A Ceased KR20170045343A (ko) 2014-09-04 2015-09-03 피부의 장벽 기능의 ｕｖ-유도 상실을 치료하는데 사용하기 위한 국소 프테로스틸벤 조성물

Country Status (11)

Country Link
US (1) US9980924B2 (enExample)
EP (1) EP3194032B1 (enExample)
JP (1) JP2017525738A (enExample)
KR (1) KR20170045343A (enExample)
CN (1) CN107106877A (enExample)
AU (1) AU2015311799A1 (enExample)
BR (1) BR112017004304B1 (enExample)
CA (1) CA2959756C (enExample)
MX (1) MX375612B (enExample)
WO (1) WO2016036999A1 (enExample)
ZA (1) ZA201701510B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX375612B (es) 2014-09-04 2025-03-06 Univ California Composiciones tópicas de pterostilbeno para utilizarse en el tratamiento de la pérdida inducida por uv de la función de barrera en la piel.
EP3501490B1 (en) * 2016-08-17 2023-08-30 Tomoike Bio Ltd. Composition for external use that includes pterostilbene glycoside
JP7061766B2 (ja) * 2017-09-20 2022-05-02 学校法人同志社 Ｄｊ－１タンパク質産生促進用組成物
CA3163065A1 (en) 2019-12-30 2021-07-08 George P. Majewski Ppar agonist complex and methods of use
EP4029496A1 (en) * 2021-01-18 2022-07-20 Universitat de València Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2820975B1 (fr) 2001-02-21 2004-03-12 Oreal Composition pour application topique comprenant au moins un hydroxystilbene et au moins un polyol pour solubiliser l'hydroxystilbene
US20090047309A1 (en) 2007-08-13 2009-02-19 Maes Daniel H Cosmetic methods and compositions for repairing human skin
US8703161B2 (en) 2007-08-13 2014-04-22 Elc Management, Llc Skin repair compositions comprising circadian gene activators and a synergistic combination of Sirt1 gene activators
US20100240767A1 (en) * 2009-03-23 2010-09-23 Muhammed Majeed Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof
EP2322159A1 (en) * 2009-10-30 2011-05-18 Green Molecular, S.L. Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
US8841350B2 (en) * 2011-05-11 2014-09-23 ChromaDex Inc. Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
JP2013075851A (ja) * 2011-09-30 2013-04-25 Fujifilm Corp 皮膚外用剤
US20130296440A1 (en) 2012-05-01 2013-11-07 ChromaDex Inc. Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
CN103239540B (zh) * 2013-04-03 2014-11-12 广东药学院 一种凉血愈伤方提取物及治疗皮肤烧伤的复方白藜芦醇凉血愈伤油制剂
WO2016037007A1 (en) 2014-09-04 2016-03-10 The Regents Of The University Of California Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia
MX375612B (es) 2014-09-04 2025-03-06 Univ California Composiciones tópicas de pterostilbeno para utilizarse en el tratamiento de la pérdida inducida por uv de la función de barrera en la piel.

Also Published As

Publication number Publication date
US20160067194A1 (en) 2016-03-10
MX2017002818A (es) 2017-08-02
BR112017004304B1 (pt) 2020-12-08
EP3194032B1 (en) 2021-06-23
CA2959756C (en) 2023-02-28
AU2015311799A1 (en) 2017-03-30
BR112017004304A2 (pt) 2017-12-05
JP2017525738A (ja) 2017-09-07
EP3194032A4 (en) 2018-05-23
CN107106877A (zh) 2017-08-29
US9980924B2 (en) 2018-05-29
CA2959756A1 (en) 2016-03-10
WO2016036999A1 (en) 2016-03-10
MX375612B (es) 2025-03-06
EP3194032A1 (en) 2017-07-26
ZA201701510B (en) 2018-11-28

Similar Documents

Publication Publication Date Title
Yarosh et al. Anti-inflammatory activity in skin by biomimetic of Evodia rutaecarpa extract from traditional Chinese medicine
US9980924B2 (en) Topical pterostilbene compositions for use in treating UV-induced loss of barrier function in skin
Perugini et al. Efficacy of oleuropein against UVB irradiation: preliminary evaluation
US8029770B2 (en) Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer
JP5620443B2 (ja) 抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ
CN105873937A (zh) 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物
CN117377475B (zh) 治疗与糖尿病性周围神经病变相关的疼痛
HK1252899A1 (en) Composition and association of sunscreens for photostabilizing butyl methoxydibenzoylmethane (bmdbm)
WO2020028875A1 (en) Sunscreen composition comprising cannabis extracts
US10226435B2 (en) Compositions and methods for restoring the stratum corneum and treating dermatological diseases
Engel et al. Anti‐inflammatory effect of pimecrolimus in the sodium lauryl sulphate test
Maden Epidermal skin barrier and skin care in Rosacea: A narrative review
Moglia et al. Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses
EP1784225B1 (en) Biomimetic of evodia rutaecarpa fruit extract for amelioration of inflammation
WO2016037007A1 (en) Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia
KR20070074624A (ko) 매크롤라이드 ｔ-세포 면역조절물질 및 광노화방지제를포함하는 제약 조성물
HK1241310B (en) Topical pterostilbene compositions for use in treating loss of barrier function in skin in burn injurys
US20230172960A1 (en) Topical capecitabine for the treatment of hyperproliferative skin conditions
Kim et al. Chemical stability and in vitro and clinical efficacy of a novel hybrid retinoid derivative, bis-retinamido methylpentane
JP2020502279A (ja) 色素沈着過剰障害の処置方法
TW201632182A (zh) 治療皮膚之腫瘤及癌前病理的雷公藤內酯及其衍生物
KR20160064262A (ko) 인도시아닌 그린-함유 조성물의 광민감제 및 이를 포함하는 조성물
Huang et al. Innovative Safe Sunscreens Technology: Evaluation of Skin Penetration Through In Vitro/In Vivo Assays and Environmental Friendliness
KR101831352B1 (ko) 인도시아닌 그린-함유 조성물의 광민감제 및 이를 포함하는 조성물
Kek et al. In situ measurement of spectral changes in the anterior eye following application of ultraviolet-absorbing compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination